SCHEMBL3343847

SCHEMBL3343847

COc1ccc(-c2c[nH]c(=S)[nH]2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
GFER P55789 4/20 0.58
KDM4E B2RXH2 4/20 0.58
GAA P10253 3/20 0.58
HDAC8 Q9BY41 1/20 0.55
MAPT P10636 5/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.51
CACNA1B Q00975 1/20 0.51
APBA1 Q02410 1/20 0.51
MCL1 Q07820 1/20 0.51
HPGD P15428 4/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
TP53 P04637 1/20 0.49
ALOX12 P18054 1/20 0.49
MAP2K1 Q02750 1/20 0.46
SCN4A P35499 1/20 0.44
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640473 0.80 GAA (0.56) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL3342864 0.78 CYP2D6 (0.54) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL640048 0.77 GFER (0.53) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL3343223 0.77 NPC1 (0.49) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL26034660 0.76 ALDH1A1 (0.49) ALDH1A1KDM4EHDAC8MAPTMCL1
SCHEMBL639436 0.75 KDM4E (0.50) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL3343038 0.75 GFER (0.64) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL3343853 0.75 GFER (0.64) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL3342194 0.75 KDM4E (0.64) ALDH1A1GFERKDM4EGAAHDAC8
SCHEMBL638777 0.74 GFER (0.58) ALDH1A1GFERKDM4EGAAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE 2010-06-24 US claimed
EP-2164486-A2 USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS Galderma Research & Development (FR) 2010-03-24 EP claimed
WO-2008152330-A2 USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO claimed
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE 2010-06-24 US disclosed
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE 2010-06-24 US disclosed
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE 2010-06-24 US disclosed
EP-2164486-A2 USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS Galderma Research & Development (FR) 2010-03-24 EP disclosed
WO-2008152330-A2 USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed
WO-2008152330-A2 USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160401-A1 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH TYR, TH, PAH ALDH1A1 37/4885GFER 2509/4885KDM4E 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.